Period until the progression of myelodysplastic syndrome 6 years (study treatment and follow up) [clinicaltrials_resource:b9af1fd35617b194adbdba026a743648]
To assess if treatment with Revlimid (Lenalidomide) extends the period until the progression to MDS of(5q) considered as transfusion independent, documented verification that the patient suffering from anemia due to MDS requires transfusion of at least 2 UCH/56 days (2 months) with a minimum follow up of 112 days (4 months). Revlimid will be compared to the current standard treatment for patients with low risk MDS associated with the loss of 5q without transfusion dependent anemia, which is the therapeutic abstention and monitoring until its progression.
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Period until the progression of myelodysplastic syndrome 6 years (study treatment and follow up) [clinicaltrials_resource:b9af1fd35617b194adbdba026a743648]
To assess if treatment with Revlimid (Lenalidomide) extends the period until the progression to MDS of(5q) considered as transfusion independent, documented verification that the patient suffering from anemia due to MDS requires transfusion of at least 2 UCH/56 days (2 months) with a minimum follow up of 112 days (4 months). Revlimid will be compared to the current standard treatment for patients with low risk MDS associated with the loss of 5q without transfusion dependent anemia, which is the therapeutic abstention and monitoring until its progression.
Bio2RDF identifier
b9af1fd35617b194adbdba026a743648
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b9af1fd35617b194adbdba026a743648
measure [clinicaltrials_vocabulary:measure]
Period until the progression of myelodysplastic syndrome
time frame [clinicaltrials_vocabulary:time-frame]
6 years (study treatment and follow up)
description
To assess if treatment with Re ...... itoring until its progression.
identifier
clinicaltrials_resource:b9af1fd35617b194adbdba026a743648
title
Period until the progression o ...... study treatment and follow up)
@en
type
label
Period until the progression o ...... f1fd35617b194adbdba026a743648]
@en